ANXA5 and neoplasm: Similar to that observed in TC-1 tumor model, AnxA5-AH5 administration following cisplatin significantly increased the CD8+ T cell and CD4+ T cell populations and reduced the Tregs and MDSCs population in the TME (Supplementary Fig. 13c).